[go: up one dir, main page]

WO2001000635A3 - Derivatives of (3s) tetrahydro-3-furanyl (1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate - Google Patents

Derivatives of (3s) tetrahydro-3-furanyl (1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate Download PDF

Info

Publication number
WO2001000635A3
WO2001000635A3 PCT/EP2000/005785 EP0005785W WO0100635A3 WO 2001000635 A3 WO2001000635 A3 WO 2001000635A3 EP 0005785 W EP0005785 W EP 0005785W WO 0100635 A3 WO0100635 A3 WO 0100635A3
Authority
WO
WIPO (PCT)
Prior art keywords
propylcarbamate
phosphonooxy
aminophenyl
furanyl
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/005785
Other languages
French (fr)
Other versions
WO2001000635A2 (en
Inventor
Andrew David Searle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to AU58181/00A priority Critical patent/AU5818100A/en
Publication of WO2001000635A2 publication Critical patent/WO2001000635A2/en
Anticipated expiration legal-status Critical
Publication of WO2001000635A3 publication Critical patent/WO2001000635A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention relates to derivatives of (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy) propylcarbamate, to processes for their preparation, and to their use as analytical markers and in the treatment of diseases caused by retroviruses.
PCT/EP2000/005785 1999-06-24 2000-06-23 Derivatives of (3s) tetrahydro-3-furanyl (1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate Ceased WO2001000635A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU58181/00A AU5818100A (en) 1999-06-24 2000-06-23 Derivatives of (3s) tetrahydro-3-furanyl (1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzy -2-(phosphonooxy)propylcarbamate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9914821.5A GB9914821D0 (en) 1999-06-24 1999-06-24 Compounds
GB9914821.5 1999-06-24

Publications (2)

Publication Number Publication Date
WO2001000635A2 WO2001000635A2 (en) 2001-01-04
WO2001000635A3 true WO2001000635A3 (en) 2003-04-17

Family

ID=10856016

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/005785 Ceased WO2001000635A2 (en) 1999-06-24 2000-06-23 Derivatives of (3s) tetrahydro-3-furanyl (1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate

Country Status (3)

Country Link
AU (1) AU5818100A (en)
GB (1) GB9914821D0 (en)
WO (1) WO2001000635A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US20050131042A1 (en) * 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
US8193227B2 (en) 2003-12-11 2012-06-05 Abbott Laboratories HIV protease inhibiting compounds
BRPI0823520A2 (en) 2007-06-12 2013-12-17 Concert Pharmaceuticals Inc AZAPEPTIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
AU2010296846B2 (en) * 2009-09-16 2013-11-28 Sun Pharmaceutical Industries Limited Process for the preparation of fosamprenavir calcium
EP2507250A1 (en) * 2010-01-07 2012-10-10 Pliva Hrvastka D.O.O. Solid state forms of fosamprenavir calcium salt and process for preparation thereof
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005639A1 (en) * 1992-09-08 1994-03-17 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of hiv-aspartyl protease
WO1999033815A1 (en) * 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors
WO2000004033A1 (en) * 1998-07-18 2000-01-27 Glaxo Group Limited Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino] -1-benzyl-2- (phosphonooxy) propylcarbamate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005639A1 (en) * 1992-09-08 1994-03-17 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of hiv-aspartyl protease
WO1999033815A1 (en) * 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors
WO2000004033A1 (en) * 1998-07-18 2000-01-27 Glaxo Group Limited Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino] -1-benzyl-2- (phosphonooxy) propylcarbamate

Also Published As

Publication number Publication date
GB9914821D0 (en) 1999-08-25
WO2001000635A2 (en) 2001-01-04
AU5818100A (en) 2001-01-31

Similar Documents

Publication Publication Date Title
AP2001002039A0 (en) Calcium (3s) tetrahydro-3-furanyl (IS,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate.
WO2003031462A3 (en) Nogo receptor-mediated blockade of axonal growth
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
AU5812400A (en) Carrier-drug conjugate
TNSN97009A1 (en) 2-OXO- AND 2-THIO- 1,2- DIHYDROQUINOLEINYL-OXAZOLIDINONES.
WO2000066528A3 (en) Quinones for treatment of diseases
WO2001079164A3 (en) N-substituted dithiocarbamates for the treatment of biological disorders
WO2001000635A3 (en) Derivatives of (3s) tetrahydro-3-furanyl (1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate
AU5539798A (en) Sulfonamide-substituted chromans, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
WO2003004517A3 (en) Peyers's patch and/or m-celle targeting ligands
WO2001096873A3 (en) Method for identifying apoptosis-modified proteins
WO1998030190A3 (en) Colon cancer KH-1 and N3 antigens
WO2002066492A3 (en) Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof
EP0302303A3 (en) Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation
CA2387600A1 (en) Novel fusidic acid derivatives
WO1999050671A3 (en) Toso as a target for drug screening
EP1607399A3 (en) BIS-(N,N'-BIS-(2-Haloethyl)Amino) Phosphoramidates as antitumor agents
WO2003022883A3 (en) Use of proteins for the production of a medicament for stimulating the innate non specific immune system
WO2002101394A3 (en) Screening method which uses bnpi and dnpi
WO2007044574A3 (en) Pharmaceutical compositions, methods of preparation thereof, and methods of treatment
WO1999021538A3 (en) Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye
AU5386098A (en) Sulfonamide-substituted compounds, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them
AU2002241416A1 (en) Dermatological agent for the treatment of skin trauma, especially in burn conditions
ECSP993057A (en) TETRAHIDRO -3-FURANIL (1S, 2R) -3 - [[(4-AMINOFENIL] SULFONIL)] (ISOBUTIL) AMINO] -1- BENCIL-2 - (FOSFONOOXI) PROPILCARBAMATO DE CALCIO
AU2001271964A1 (en) Improved preparation of (4r, 5s, 6s)-3-(((2r,3r)-2-((((s)-2-amino-3-methyl-1-oxobutyl)methyl) tetrahydro-3-furanyl)thio)-6-((r)-1-hydroxyethyl)-4-methyl-7 -oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP